Oryzon Secures U.S. Patent Allowance For Vafidemstat In Borderline Personality Disorder Treatment

Oryzon Genomics has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering methods of treating borderline personality disorder (BPD). The patent relates to vafidemstat, the company’s LSD1 inhibitor currently in clinical development for psychiatric conditions, and strengthens its intellectual property position in central nervous system (CNS) disorders.

“This U.S. Notice of Allowance reinforces our intellectual property position for vafidemstat in borderline personality disorder and supports its long-term development and commercial potential in an area of significant unmet medical need,” said Neus Virgili, Oryzon’s Chief IP Officer.

The allowed claims specifically focus on the use of LSD1 inhibitors to address non-aggressive symptoms of BPD, complementing Oryzon’s existing patents targeting aggression-related aspects of the disorder. Once formally granted, the patent is expected to remain valid until at least 2040, excluding any additional term adjustments or extensions that may be applied.

Oryzon has also secured or advanced similar patent protections for vafidemstat across multiple regions, including Europe, Japan, Australia, and others, with further applications under review globally. In addition, the company holds a broader portfolio of patents covering the use of vafidemstat in CNS disorders such as aggression and social withdrawal, with protections expected to extend until at least 2038, reinforcing its long-term strategy in neuropsychiatric therapeutics.